A validated and robust bioassay is of paramount importance in the various stages of biosimilar development to ensure efficacy, quality and potency. The complement-dependent cytotoxicity assay was validated over six simulated potencies and found specific for rituximab-like antibodies. The bioassay was found robust with linearity parameter R 2 = 0.99, %GCV for precision and accuracy was less than 20% for >40 individual performances. Detailed set of system suitability and sample acceptance criteria was determined. The study may play a key part in the development of written and physical potency reference standards for incorporation in different pharmacopeia for effective biosimilar development and regulation.
BIOSIMILARS are the imitation biological products of their originator molecules with similarity in quality, efficacy and safety 1 . Biosimilars cost less than their originator products owing to their shortened clinical trials 2 . The first biosimilar was approved for use in the European Union (EU) in 2006. A better acceptance of biosimilars will help lessen the burden of healthcare systems through price competition and ease of patient access to vital drugs 3 . Compared to chemical generics, biosimilars are stringently evaluated for quality, safety and efficacy 4 . According to guidance documents on biosimilars issued by European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), pharmacologic activity of protein products showing biosimilarity should be essentially demonstrated by in vitro and/or in vivo functional assays 5, 6 . Guidelines on similar biologics, jointly prepared by the Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT), New Delhi in 2016, state in vitro and/or in vivo potency assays as one of the critical quality attributes (CQAs) for establishing comparable safety and efficacy of similar biologics and reference biologics 7 .
Rituximab is a chimeric monoclonal antibody wherein mouse variable domains have been grafted over the effector regions derived from humans 8 . The primary target of the antibody is the protein CD20, which is abundantly expressed on the surface of immune system B cells 9 . This mechanism makes rituximab an effective therapy for destruction of B cells and hence is used in the treatment of diseases which are associated with abnormal proliferation, overactive or dysfunctional B cells, such as numerous lymphomas, leukaemia, transplant rejection and autoimmune disorders 10 . A specific, sensitive and robust bio-analytical method for potency or bioactivity evaluation of biosimilars is critical for the development and successful conduct of pre-clinical and clinical pharmacology studies. In vitro studies are beneficial in determining the mechanisms of action in a rapid, rigorous and focused way 11 . Previous in vitro studies on rituximab suggest three mechanisms for target-cell killing, viz. complement-mediated cytotoxicity of B cells (better known as complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis of B cells via activation of caspase 3 (ref. 12) . Furthermore, it has been proposed and reported in previous studies that CDC is the main pathway involved in in vivo effectiveness of rituximab. It has been further suggested that antibody showing poor sensitivity to CDC in vitro might show poor clinical response, whereas antibody showing good sensitivity to CDC might show better response to rituximab treatment 13 . Taking clues from these proposals we have developed and validated a robust, efficient and costeffective CDC-based assay for potency testing of rituximab-like biosimilars. This also encompasses the detailed suitability criteria designed for both the assay and the sample, thus assisting in the batch release and regulation of rituximab-like biosimilars. The study may play a key part in the development of written and physical reference standards for incorporation in different pharmacopeia for effective regulation of the drug.
Chemicals and reagents used in the assay were of cell culture-grade. The WIL2-S cells were procured from American Type Culture Collection (ATCC). RPMI-1640 and FBS were purchased from Sigma-Aldrich, USA. Penicillin and streptomycin solution was purchased from MP Biomedicals, Navi Mumbai, India. Human complement was purchased from Quidel, California, USA. Innovator's rituximab (Ristova) was obtained from the M/s F. Hoffman-La Roche Ltd, Germany for standard solution preparation. All equipment used for CDC assay and validation studies were calibrated and validated. Sterilized plastic ware such as tissue culture flasks, serological pipettes, falcons and 96-well plates was purchased from Nunc, New York, USA.
The WIL2-S cells were grown as suspension in RPMI-1640 medium supplemented with 10% (v/v) foetal bovine serum (heat-inactivated), 5 ml penicillin and streptomycin solution (final concentration to be 100-120 units/ml penicillin and 0.10-0.12 mg/ml streptomycin), 0.25% of glucose and 1 mM sodium pyruvate. Viability and cell count before seeding were carried out using the Neubauer chamber and trypan blue exclusion method. Cells were seeded at the density of 0.1-0.2  10 6 cells/ml and maintained under a fully humidified atmosphere of 5% CO 2 at 37C.
CDC assay for potency testing of rituximab was carried out in RPMI-1640 medium supplemented with 1.3% (w/v) bovine serum albumin, 1% penicillin and streptomycin solution (final concentration to be 100-120 units/ml penicillin and 0.10-0.12 mg/ml streptomycin) and 2% 1 M HEPES solution 14 . The assay medium was filtered aseptically through 0.22 m filter using sterile filtration assembly and stored at 2-8C.
Dilution scheme used was modified according to the USP Medicines Compendium 14 . Rituximab in case of both reference standard and sample (10 mg/ml) was diluted 100 times through serial dilution to obtain the working stock of 100 g/ml. Dilutions from the working stock were prepared in assay block using the dilution scheme ( Table 1) .
As shown in Table 2 , assay plates for carrying out CDC assay were setup. Briefly, 50 l of dilutions prepared were transferred to each assay plate in duplicates. To these dilutions, 50 l of WIL2-S cell suspension of density 0.8-1.2  10 6 cells was added. Further, normal human complement was diluted 2.5 times in cold assay medium. Then 50 l of this diluted complement was added to the reaction mixture. The plates were incubated for 2 h in 5% CO 2 at 37C. Assay medium control (wherein no reaction component was added), complement control (no antibody was added) and cell culture control (neither antibody nor complement was added) were also setup along with the tests. After 2 h incubation, 50 l of Alamar Blue was added to each well. The plates were further incubated as in the previous conditions for 16-20 h. After incubation, plates were read for fluorescence using a spectrofluorometer SpectraMax Gemini Spectrofluorometer, Molecular Devices, Shanghai, China at 530/590 nm excitation/emission with cut-off at 590 nm. More than 42 individual performances were conducted to determine the assay suitability and system suitability criteria.
The relative fluorescent units (RFU) signals obtained from SpectraMax plate reader were fit into nonlinear four parameter logistic (4PL) model 15 . The four parameters that need to be estimated in order to 'fit the curve' are A, B, C and D, where A and D are the upper and lower asymptotes respectively, B is the slope and C is the point of infection or half maximal effective concentration (EC 50 ). The equation for the model is
where x is the independent variable and y is the dependent variable, just as in the linear model 15 . Figure 1 . Test for specificity. Dose-response curve of rituximab, adalimumab and trastuzumab using complement-dependent cytotoxicity assay.
The system suitability criteria (SSC) and sample acceptance criteria (SAC) were established based on 95% confidence intervals (mean  2SD) or 99% confidence intervals (mean  2SD). For determining assay suitability criteria for the bioassay, a detailed comparison of all the 4PL fit terms, viz. R 2 of internal reference standard (IRS) assay, EC 50 , slope, A/D ratio, mean RFU of cell control, mean RFU of highest concentration of IRS and fold response of n = 12 (pre-validation) performances of bioassay was carried out. Similar comparison was done for SSC, viz. % relative potency to IRS and 95% confidence intervals.
The validation parameters, viz. relative accuracy, specificity, intermediate precision, linearity and range of the method were estimated in the method validation study 9, 16 . Rituximab test samples were prepared to yield simulated potencies of 50%, 71%, 100%, 122%, 150% and 200% for each parameter.
Specificity parameter was validated to rule out matrix interference and separation selectivity. Anti TNF alpha monoclonal antibody (adalimumab) and anti HER2/neu receptor monoclonal antibody (trastuzumab) samples were put to test along with IRS in a plate to assess the method specificity for rituximab-like antibodies.
For accessing the linearity and range of method, six concentrations of standards with simulated potencies of 50%, 71%, 100%, 122%, 150% and 200% were put to test. A calibration curve for ln (% simulated nominal potencies) versus ln (% observed relative potencies) was plotted and the obtained data were subjected to regression analysis by the least squares method as described by Dafale et al. 17 .
Repeatability of the method was determined by carrying out CDC assays at various time slots by the same analyst and expressed in the terms of geometric coefficient of variation (%GCV). %GCV = 100  (e SD -1)%, where SD is the standard deviation of log-transformed relative potency measurements. Intermediate precision of the method was assessed by replicating the assay using three different analysts as well as different time periods, and expressed in terms of %GCV (ref. 17) .
Accuracy of the bioassay was determined by calculating % relative bias using results of different performances 18 %Relative bias = 100  ((measured potency/ target potency) -1)%.
Biosimilars represent a relatively heterogeneous class of medicinal products that makes their regulation quite challenging. This heterogeneity may be due to higher molecular weight and complexity in structure and function that can be affected by changes in the manufacturing process 19 . According to most guidance documents issued on the regulation of biosimilars, suitable biological assays are required to assess the functional activity and determine the mechanism of action and clinical effect of the product [5] [6] [7] . Rituximab has been the choice of treatment in B cell malignancies due to its action against CD20 protein expressed on the surface of proliferating or dysfunctional B cells 8, 9 . It is known to act through CDC, ADCC or via activation of caspase 3 under in vivo conditions. However, previous studies suggested that in vitro CDC response has a direct correlation with effectiveness of rituximab in clinical trials 10 . Many reports have correlated the efficacy of rituximab with CD20 expression [9] [10] [11] [12] . A simple and robust CDC bioassay has been developed and validated here for assisting the lot release or regulations of rituximab-like biosimilars. To the best of our knowledge, there are no previous studies wherein a detailed set of the SAC and SSC have been chalked out to establish the biological activity of rituximab like biosimilar. This will also assist in the development of written and physical reference standards for all pharmacopeia.
The developed CDC bioassay was validated for parameters like specificity, linearity and range, repeatability, intermediate precision and accuracy.
Trastuzumab and adalimumab were used as antibody instead of rituximab for testing the specificity of the assay. It can be inferred from Figure 1 that no significant dose response is observed when rituximab was replaced by any other antibody in the assay. Thus, the CDC assay developed complies with criteria of specificity in accordance to the United States Pharmacopeia 16 . Figure 2 shows that linear regression model is obtained for observed and simulated ln(%RP) across the six simulated potency levels. The representative linear equation is y = 0.9772x + 0.107. Regression lines for two analysts are nearly coincident and further analysis shows that the method is linear over the range 50-200%, wherein the observed relative potency at each individual simulated level is within 80-120% of the expected potency. Also, the assay complies with the parameter of linearity since relative potency at each individual simulated level is directly proportional to its concentration with the value of R 2 = 0.99 (ref. 20) . The reported CDC assay complies with the parameter of precision, which was demonstrated through repeatability and intermediate precision data. For seven assays carried out by a single analyst, %GCV at 100% simulated potency was 6.14% (Table 3) . It can also be inferred from Table 3 that the intermediate precision in terms of %GCV for the assay is only 7.09% at 100% simulated potency. The %GCV for precision (repeatability and intermediate precision) is less than 20% over more than 40 individual performances. According to Reed et al. 15 and most international guidelines, %CV should not be more than 20% for bioassays to be precise.
The reported assay complied with the parameter of accuracy since the relative bias obtained over numerous performances was only -0.24 at 100% simulated potency (Table 4) , which is well in accordance with the criteria of  10% for normally distributed data 16 . The %GCV was not more than 20% for any of the simulated potencies tested.
SSC and SAC are necessary to ensure the quality of bioassay results 21 . Based on the 4PL curve fit results obtained from all the performances, a detailed set of SSC or assay acceptance criteria and SAC was determined (Tables 5 and 6 ). SSC and SAC are primarily based on comparison of dose-response curves of the test sample with a reference sample and will be useful in judging the validity of the assay. SSC and SAC can be reviewed and modified to narrow down the ranges as more data are acquired. These criteria can be critical for assisting the quality assurance of rituximab-like similar biologics. Currently, there are no monographs in any of the pharmacopeia of the world for quality control testing of rituximab-like antibodies. Hence the present study may play a critical role in the development of physical and written reference standards for incorporation in different pharmacopeia.
Extensive performances were carried out to determine SSC and SAC for CDC assay of rituximab-like similar biologics. The reported bioassay is a simple, robust method for assisting the regulation and quality assurance of rituximab-like similar biologics in an efficient way. The study may play a critical role in the development of physical reference standards and monographs for incorporation in different pharmacopeia. Though the bioassay is a critical quality attribute for regulation of similar biologics, however they need to qualify the other physiochemical and bioanalytical parameters supported by clinical trial data before hitting the market and to ensure consistency in production for the lot release.
